Ideaya Biosciences Inc. is a biotechnology company focused on the discovery and development of targeted therapies for cancer. The company was founded in 2015 and is headquartered in South San Francisco, California, United States.
Ideaya Biosciences utilizes a precision medicine approach to identify and develop novel therapies that can effectively target specific genetic alterations in cancer cells. By leveraging its expertise in synthetic lethality and immuno-oncology, the company aims to address unmet needs in oncology treatment.
The company's pipeline consists of multiple investigational compounds, each targeting different pathways and mechanisms involved in cancer growth and survival. Ideaya Biosciences uses a combination of internal research and development efforts as well as strategic collaborations with academic institutions and pharmaceutical partners to advance its pipeline programs.
In terms of going public, Ideaya Biosciences completed its initial public offering (IPO) in May 2019. Through the IPO, the company raised capital to support its research and development activities, including the advancement of its pipeline candidates into clinical trials.
Since going public, Ideaya Biosciences has continued to make progress in its drug discovery and development programs. The company focuses on conducting preclinical and clinical studies to assess the safety and efficacy of its investigational compounds in various cancer types. It aims to bring innovative therapies to patients who may benefit from targeted treatment approaches.